Skip to main content
. 2020 Jan 31;189(4):731–744. doi: 10.1111/bjh.16435

Figure 4.

Figure 4

Copanlisib inhibited NKTCL tumour cell growth in vitro and in vivo. (A) 0·5 µM of copanlisib but not alpelisib, idelalisib abolished NKS1 and YT cell proliferation. (B) Tumour growth curves of the NKS1 xenograft model. treatment with 25 mg/kg copanlisib significantly decreases tumour growth compared with vehicle‐control‐only treated mice. (C) Copanlisib inhibited phosphorylation of AKT, EIF4EBP1 and STAT3, and increased cleaved‐PAPRP protein level in NKS1‐engrafted tumours. Error bars indicate the standard error of the mean. *, P < 0·05, **, P < 0·01. [Colour figure can be viewed at wileyonlinelibrary.com]